CAMBRIDGE, Mass., April 8, 2026—Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI® algorithm for cardiac amyloidosis (CA) – the…

CAMBRIDGE, Mass. – March 28, 2026 – Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled…

Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support  CAMBRIDGE, Mass., March 24, 2026—Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana Inc., a leader in AI-powered cardiovascular detection algorithms, today announced the appointment of Kevin Ballinger and Jean-Luc Butel to its Board of Directors. In their roles, Ballinger and…

Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, today announced…

Company to present four studies, including a late-breaking featured science presentation, and host interactive experiences demonstrating AI’s role in cardiovascular care

Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystem

New investment fuels growth of ECG-AI platform and development of perioperative AI capabilities

#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…

Anumana appoints new President and COO